Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 9 min 54 sec ago

ClearSpec LLC Signs Distribution Agreement with McKesson Medical-Surgical

Tue, 05/13/2014 - 14:49
Novel device scientifically proven to improve visualization of the cervix BOCA RATON, Fla.--(Healthcare Sales & Marketing Network)--ClearSpec LLC announced today that it has entered into a distribution agreement with McKesson Medical-Surgical Inc. (“McK...
Devices, Distribution
ClearSpec, McKesson Medical-Surgical, Vaginal Speculum

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve(R) 100 Novolimus Eluting Coronary Scaffold System

Tue, 05/13/2014 - 14:47
Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)--Elixir Medical Corporation, a developer of product platforms th...
Devices, Interventional Cardiology, Regulatory
Elixir Medical, DESolve 100, Coronary Scaffold, coronary stent

GE Healthcare and CorTechs Labs Inc. Announce Strategic Agreement to Co-Market NeuroQuant(R), Comprehensive Solutions for Quantifying Brain Volume Loss

Tue, 05/13/2014 - 14:43
Advanced magnetic resonance imaging (MRI) solutions combined with the innovative NeuroQuant software provides invaluable information to neurologists and radiologists MILAN--(Healthcare Sales & Marketing Network)--Today at the joint meeting of the Intern...
Devices, Neurology, Radiology, Distribution
GE Healthcare, CorTechs Labs, NeuroQuant

IsoRay's Liquid Cesium-131 (Cesitrex(R)) Recieves Final Regulatory Approval for Use in GliaSite(R) Brain Cancer Treatment System

Mon, 05/12/2014 - 15:39
Revolutionary Therapy Now Available for Brain Cancers RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today annou...
Devices, Oncology, Regulatory
IsoRay, Cesitrex, Cesium-131, GliaSite, brachytherapy, radiotherapy

Cardinal Health Completes Acquisition of AccessClosure

Mon, 05/12/2014 - 15:35
Company expands portfolio of physician preference items that meet increasing demand for high quality, cost-efficient solutions DUBLIN, Ohio, May 12, 2014 -- (Healthcare Sales & Marketing Network) -- Cardinal Health today announced the completion of the...
Devices, Interventional, Mergers & Acquisitions
Cardinal Health, AccessClosure, Mynx, vascular closure

Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding

Mon, 05/12/2014 - 15:29
Link between lysosome-based genetic disorders and neurodegenerative diseases to be explored as foundation for new therapeutics CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertis...
Biopharmaceuticals, Neurology, Venture Capital
Lysosomal Therapeutics, Parkinson’s disease

Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs

Mon, 05/12/2014 - 15:24
REDWOOD CITY, Calif., May 12, 2014 -- (Healthcare Sales & Marketing Network) -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D. as Senior Vice President, Global Regulatory Affairs. Dr. Bell j...
Biopharmaceuticals, Personnel
Coherus Biosciences, biosimilar

Beryllium Launches and Expands Leadership Team

Mon, 05/12/2014 - 15:22
New company created to shape the future of collaborative drug discovery BEDFORD, Mass.--(Healthcare Sales & Marketing Network)--Beryllium announced today its formation as it recently finalized its consolidation of restructured assets from Emerald Bio an...
Biopharmaceuticals, Personnel
Beryllium

FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

Mon, 05/12/2014 - 15:19
ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(Healthcare Sales & Marketing Network)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. F...
Biopharmaceuticals, Cardiology, FDA
Merck, ZONTIVITY, vorapaxar

Allergan Board Unanimously Rejects Unsolicited Proposal from Valeant

Mon, 05/12/2014 - 15:13
Valeant Proposal Substantially Undervalues Allergan and is Not in the Best Interests of Stockholders Allergan Expects to Increase EPS by 20 to 25 Percent in 2015 and by 20 Percent CAGR over Next Five Years IRVINE, Calif.--(Healthcare Sales & Marketi...
Biopharmaceuticals, Mergers & Acquisitions
Allergan, Valeant Pharmaceuticals

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong